Introduction of Effective Drugs and Vaccines to Offer Growth Opportunities for Players in Global Hospital-acquired Pneumonia Drugs Market
Hospital-acquired pneumonia (HAP) is considered to be an important cause of morbidity and mortality. The increasing number of diseases and disorders and the longer stay in hospitals are the primary factors boosting the rise in hospital-acquired pneumonia cases across the globe. This condition is primarily caused due to multidrug-resistant microorganisms. The rising research and development activities are expected to fuel the global hospital-acquired pneumonia market in the next few years.
According to the research study presented by Transparency Market Research (TMR), the global market for hospital-acquired pneumonia drugs is projected to reach a value of US$3.8 bn by the end of 2020. In this blog, TMR provides answers to several vital questions related to the growth prospects and trends in the market.
What are the primary factors augmenting the growth of hospital-acquired pneumonia drugs market?
The increasing drug resistance among infectious microorganisms is one of the key factors increasing the chances of hospital-acquired infections, thus boosting the demand for drugs in the near future. Technological advancements and the development of innovative therapeutics and drugs to treat hospital-acquired pneumonia are also encouraging the growth of the overall market. In addition, the inefficient sterilization and unsanitary conditions in healthcare facilities in middle and low-income nations are projected to increase the prevalence of hospital-acquired pneumonia in the near future.
What are the types of drugs available in the global hospital-acquired pneumonia drugs market?
The late-stage candidates in the hospital-acquired pneumonia drugs pipeline include avibactam/ceftazidime, plazomicin, tedizolid phosphate, amikacin inhale, tazobactam/ceftolozane, and synflorix vaccine. Hospital-acquired pneumonia drug candidates in phase III are expected to be launched by the end of 2020. The key drug manufacturers in the global market are emphasizing on research activities in order to introduce new drugs and acquire the status of novel drugs in the next few years. At present, several drugs are available commercially in the global market; nevertheless, the global market for hospital-acquired pneumonia drugs holds promising and lucrative opportunities for vaccines.
How is the competitive landscape of the hospital-acquired pneumonia drugs market expected to evolve in the near future?
The demand for hospital-acquired pneumonia drugs is expected to rise significantly owing to the fact that pneumonia accounts for over 22% of the overall hospital-acquired infections at present. The conventional antibiotics are proving to be ineffective in treating multidrug-resistant organisms, resulting in a sizeable unmet demand for innovative and effective drugs for hospital-acquired pneumonia as well as other infections. Thus, a large number of pharmaceutical companies are making notable efforts to enter the market and strengthen the competition in the coming years.
The constant development of new drugs by leading companies, including Achaogen, Inc., AstraZeneca plc, Merck & Co. Inc., Sanofi, Valneva SE, and GlaxoSmithKline, Inc. is expected to encourage the growth of the market in the next few years. The advent of new formulations and vaccines by offered by GlaxoSmithKline, Inc. and Sanofi in the late stage of the pipeline is expected to contribute substantially towards the growth of the overall market.